Phase 4 N=63 Effect of Ketorolac on Post Adenotonsillectomy Pain
Obstructive Sleep Apnea
Primary: Post-Anesthesia Care Unit (PACU) Morphine Requirements — 0.033; 0.058 mg/kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=60 Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression
Post-Schizophrenic Depression
Primary: Calgary Depression Scale for Schizophrenia (CDSS) — 8.31; 8.62 score on a scale
Phase 4 N=21,442 COcoa Supplement and Multivitamin Outcomes Study
Cardiovascular Disease · Cancer
Primary: Number of Participants With Total Cardiovascular Disease (CVD) Events — 410; 456; 429; 437 Participants
Phase 4 N=150 Split Face Study of the Duration of Local Anesthetics
Anesthetics, Local
Primary: Time to Return to Baseline Sensation, as Determined by Binary Outcomes (Yes/no) in 15 Minute Increments — 54.34; 49.86; 43.13; 55.78 Minutes — p=0.93
Phase 4 N=318 Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM
Diabetes
Primary: HbA1c Level — 6.9; 6.4 percentage of glycated hemoglobin
Phase 4 N=260 SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke
Stroke
Primary: Modified Ordinal Rankin Scale (mRS) — 16; 11; 21; 23 Participants
Phase 4 N=163 Durvalumab Long-Term Safety and Efficacy Study
Solid Tumor
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 85; 1; 0; 23 Participants
Phase 4 N=28 Renin and Renal Biomarker Response to Angiotensin II
Septic Shock · Acute Kidney Injury
Primary: Change in Plasma Renin Levels — -15; 69; -6; 26 pg/mL
Phase 4 N=33 Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
Overactive Detrusor · Neurogenic Bladder
Primary: Change From Baseline in Percent of Catheterizations Without a Leaking Accident at Week 6 — -0.45; 16.91; 13.82; 15.32 percentage of point — p=0.0928
Phase 4 N=46 Wet Time for a Foam Hand Sanitizer
Hand Hygiene Effectiveness
Primary: Foam Sanitizer Wet Time Duration — 35.41 time in seconds
Phase 4 N=512 Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
Migraine
Primary: Change From Baseline in Mean Monthly Hours of at Least Moderate Headache Pain Intensity Over Months 1, 2, and 3 — -23.38; -31.33 hours/month — p=< 0.001
Phase 4 N=86 Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic
Obesity
Primary: Weight — -2.08; -3.42; -4.36; -2.4 lbs
Phase 4 N=96 Safety of Reduced Infliximab Infusion Time
Inflammatory Bowel Diseases
Primary: Number of Participants With Acute Infusion Reaction as Assessed by the Nursing Staff of the Infusion Unit — 27; 30; 0; 0 Participants
Phase 4 N=33 Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder
Attention Deficit Disorder With Hyperactivity · Conduct Disorder · Substance Abuse
Primary: Change in fMRI Measure — -0.957100; 0.572517; -0.139000; 1.876717 BOLD signal
Phase 4 N=337 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
Cushing's Disease · Acromegaly · Neuroendocrine Tumors
Primary: Incidence of Adverse Events to Evaluate Long Term Safety Data — 265; 102; 127; 39 participants